The experimental Lyme disease shot demonstrated strong protection in late-stage trials, even though it missed one secondary goal — a major step forward against the tick-borne illness affecting hundreds of thousands annually.
🔗
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-valneva-lyme-disease-shot-shows-more-than-70-efficacy-late-stage-trial-2026-03-23/
#Study #HealthNews 🌿
